title: EGFR-targeted therapy.
abstract: Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds. By using the framework of anti-EGFR inhibitors as treatment for colorectal cancer patients, we will review the knowledge we have reached until now in improving the development of a personalized cancer therapy and we will try to indicate the future challenges this field will face in the future.
authors.affiliation: Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49 bus 602 Be 3000, Leuven, Belgium. loredana_vecchione@hotmail.com
authors.forename: Loredana
authors.initials: L
authors.lastname: Vecchione
authors.forename: Bart
authors.initials: B
authors.lastname: Jacobs
authors.forename: Nicola
authors.initials: N
authors.lastname: Normanno
authors.forename: Fortunato
authors.initials: F
authors.lastname: Ciardiello
authors.forename: Sabine
authors.initials: S
authors.lastname: Tejpar
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C117307:KRAS protein, human; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins